Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
Condition(s):Prostate Cancer MetastaticLast Updated:February 7, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Prostate Cancer MetastaticLast Updated:February 7, 2024Recruiting
Condition(s):Prostatic Neoplasms, Castration-ResistantLast Updated:March 15, 2024Active, not recruiting
Condition(s):Prostate Cancer Metastatic; Castrate Resistant Prostate Cancer; Metastatic Prostate Cancer; Metastatic Prostate AdenocarcinomaLast Updated:February 26, 2024Withdrawn
Condition(s):Prostate Cancer MetastaticLast Updated:June 7, 2019Recruiting
Condition(s):Metastatic Prostate CarcinomaLast Updated:October 17, 2016Unknown status
Condition(s):Prostate CancerLast Updated:March 30, 2009Completed
Condition(s):Prostate CancerLast Updated:February 17, 2022Completed
Condition(s):Metastatic Prostate CancerLast Updated:January 5, 2024Recruiting
Condition(s):Metastatic Prostate CancerLast Updated:March 9, 2017Terminated
Condition(s):Prostate CancerLast Updated:October 1, 2012Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.